Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 8/20 | 0.78 |
| ▸ | THRB | P10828 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 6/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28685131 | 0.92 | FGFR1 (0.85) | FGFR1THRBHPGDALDH1A1LMNA | |
| SCHEMBL29987340 | 0.92 | FGFR1 (0.85) | FGFR1THRBHPGDALDH1A1LMNA | |
| SCHEMBL30343716 | 0.88 | FGFR1 (1.00) | FGFR1THRBHPGDALDH1A1LMNA | |
| SCHEMBL122653 | 0.88 | FGFR1 (1.00) | FGFR1THRBHPGDALDH1A1LMNA | |
| SCHEMBL121454 | 0.87 | FGFR1 (0.76) | FGFR1THRBHPGDALDH1A1LMNA | |
| SCHEMBL2339316 | 0.87 | FGFR1 (0.76) | FGFR1THRBHPGDALDH1A1LMNA | |
| SCHEMBL14065338 | 0.87 | FGFR1 (0.76) | FGFR1THRBHPGDALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL7986291 | 0.87 | FGFR1 (0.97) | FGFR1THRBHPGDALDH1A1LMNA | |
| SCHEMBL2342155 | 0.85 | FGFR1 (0.77) | FGFR1THRBHPGDALDH1A1LMNA | |
| SCHEMBL121458 | 0.85 | FGFR1 (0.72) | FGFR1THRBHPGDALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521448-B2 | N-substituted benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20060189629-A1 | N-substituted benzimidazolyl c-Kit inhibitors | OSI PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| EP-1664021-A1 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005021531-A1 | N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189629-A1 | N-substituted benzimidazolyl c-Kit inhibitors | KIT, CHUK, TNNI3K | FGFR1 912/4885THRB 3020/4885HPGD 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.